Advanced in Spinal Muscular Atrophy Type 1

Dr. Cuixia Tian

Pediatric Neurology | Pediatrics | Neurology
Children's Hospital Medical Center
3333 Burnet Ave, 
Cincinnati, OH 
Accepting New Patients
Advanced in Spinal Muscular Atrophy Type 1
Children's Hospital Medical Center
3333 Burnet Ave, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Cuixia Tian is a Pediatric Neurologist and a Pediatrics provider in Cincinnati, Ohio. Dr. Tian is rated as an Advanced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 1. Her top areas of expertise are Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Dysferlinopathy, and Paramyotonia Congenita. Dr. Tian is currently accepting new patients.

Her clinical research consists of co-authoring 49 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Neurology
Pediatrics
Neurology
Licenses
Pediatrics in OH
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

CHILDREN'S HOSPITAL MEDICAL CENTER
3333 Burnet Ave, Cincinnati, OH 45229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial
Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Biological
Study Drug: CAP-1002 Allogeneic Cardiosphere-Derived Cells
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

49 Total Publications

Epicardial Adipose Tissue in Duchenne Muscular Dystrophy Cardiomyopathy.
Epicardial Adipose Tissue in Duchenne Muscular Dystrophy Cardiomyopathy.
Journal: Journal of the American Heart Association
Published: October 09, 2025
Similar Doctors
Advanced in Spinal Muscular Atrophy Type 1
Dr. Eileen Broomall
Pediatric Neurology | Neurology
Advanced in Spinal Muscular Atrophy Type 1
Dr. Eileen Broomall
Pediatric Neurology | Neurology
3333 Burnet Ave, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4222
Languages Spoken:
English
See accepted insurances

Eileen Broomall is a Pediatric Neurologist and a Neurologist in Cincinnati, Ohio. Dr. Broomall is rated as an Advanced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 1. Her top areas of expertise are Seizures, Epilepsy in Children, Memory Loss, and Athetosis.

Experienced in Spinal Muscular Atrophy Type 1
Dr. Alexander M. Zygmunt
Pediatric Neurology | Pediatrics
Experienced in Spinal Muscular Atrophy Type 1
Dr. Alexander M. Zygmunt
Pediatric Neurology | Pediatrics
3333 Burnet Ave Fl 4, 
Cincinnati, OH 
 (1.1 miles away)
513-636-4222
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alexander Zygmunt is a Pediatric Neurologist and a Pediatrics provider in Cincinnati, Ohio. Dr. Zygmunt is rated as an Advanced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 1. His top areas of expertise are Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Aphantasia, and Genetic Epilepsy with Febrile Seizures Plus (GEFS+). Dr. Zygmunt is currently accepting new patients.

Experienced in Spinal Muscular Atrophy Type 1
Dr. Charulata Venkatesan
Pediatric Neurology | Neurology
Experienced in Spinal Muscular Atrophy Type 1
Dr. Charulata Venkatesan
Pediatric Neurology | Neurology
3333 Burnet Ave, Ml 2015, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4222
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charulata Venkatesan is a Pediatric Neurologist and a Neurologist in Cincinnati, Ohio. Dr. Venkatesan is rated as an Advanced provider by MediFind in the treatment of Spinal Muscular Atrophy Type 1. Her top areas of expertise are Bone Dysplasia Corpus Callosum Agenesis, Aicardi Syndrome, Corpus Callosum Agenesis, and Acrocallosal Syndrome. Dr. Venkatesan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tian's expertise for a condition
ConditionClose
View All 22 Advanced Conditions
View All 163 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile